Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics Inc (PSTV)
NASDAQ:PSTV
Total Valuation
Plus Therapeutics has a market cap or net worth of $12.75M. The enterprise value is $6.54M.
Market Cap$12.75M
Enterprise Value$6.54M
Share Statistics
Plus Therapeutics has 17.00M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding17.00M
Owned by Insiders12.45%
Owned by Instutions9.51%
Financial Efficiency
Plus Therapeutics’s return on equity (ROE) is 9.88 and return on invested capital (ROIC) is -280.03%.
Return on Equity (ROE)987.83%
Return on Assets (ROA)-116.93%
Return on Invested Capital (ROIC)-280.03%
Return on Capital Employed (ROCE)-2015.28%
Revenue Per Employee$213,450
Profits Per Employee-$644,250
Employee Count20
Asset Turnover0.43
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Plus Therapeutics is -0.41. Plus Therapeutics’s PEG ratio is <0.01.
PE Ratio-0.41
PS Ratio1.12
PB Ratio-4.08
Price to Fair Value-4.08
Price to FCF-0.42
Price to Operating Cash Flow-0.43
PEG Ratio<0.01
Income Statement
In the last 12 months, Plus Therapeutics had revenue of $4.27M and earned -$12.88M in profits. Earnings per share was -$2.41.
Revenue$4.27M
Gross Profit$1.13M
Operating Income-$14.65M
Pretax Income-$12.88M
Net Income-$12.88M
EBITDA-11.90M
Earnings Per Share (EPS)-2.41
Cash Flow
In the last 12 months, operating cash flow was -$11.22M and capital expenditures -$722.00K, giving a free cash flow of -$11.95M billion.
Operating Cash Flow-$11.22M
Free Cash Flow-$11.95M
Free Cash Flow per Share-$0.70
Dividends & Yields
Plus Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-236.71%
Earnings Yield-242.26%
Stock Price Statistics
Beta1.92
52-Week Price Change-63.22%
50-Day Moving Average1.03
200-Day Moving Average1.31
Relative Strength Index (RSI)43.60
Average Volume (3m)32.75M
Important Dates
Plus Therapeutics upcoming earnings date is Apr 17, 2025, After Close.
Last Earnings DateMar 27, 2025
Next Earnings DateApr 17, 2025
Ex-Dividend Date―
Financial Position
Plus Therapeutics as a current ratio of 0.92, with Debt / Equity ratio of -3.10
Current Ratio0.92
Quick Ratio0.92
Debt to Market Cap0.72
Net Debt to EBITDA0.34
Interest Coverage Ratio-33.72
Taxes
In the past 12 months, Plus Therapeutics has paid $280.91K in taxes.
Income Tax$280.91K
Effective Tax Rate0.00%
Enterprise Valuation
Plus Therapeutics EV to EBITDA ratio is -0.09, with an EV/FCF ratio of -0.09.
EV to Sales0.23
EV to EBITDA-0.09
EV to Free Cash Flow-0.09
EV to Operating Cash Flow-0.09
Balance Sheet
Plus Therapeutics has $4.79M in cash and marketable securities with $3.40M in debt, giving a net cash position of -$1.39M billion.
Cash & Marketable Securities$4.79M
Total Debt$3.40M
Net Cash-$1.39M
Net Cash Per Share-$0.08
Tangible Book Value Per Share-$0.56
Margins
Gross margin is -97.23%, with operating margin of -271.14%, and net profit margin of -271.04%.
Gross Margin-97.23%
Operating Margin-271.14%
Pretax Margin-271.04%
Net Profit Margin-271.04%
EBITDA Margin-258.36%
EBIT Margin-271.14%
Analyst Forecast
The average price target for Plus Therapeutics is $6.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.17
Price Target Upside864.06%
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast18.54%
EPS Growth Forecast50.37%